Outcome of invasive lobular (ILC) vs ductal (IDC) early breast carcinomas (EBC): 8-year follow-up results in patients (pts) of French Adjuvant Study Group (FASG) trials. S. Abadie-Lacourtoisie, A. Lortholary, E. Fondrinier, J.-M. Pion, L. Gladieff, D. Gedouin, P. Fumoleau, M.-J. Goudier, M. Namer, I. Chapelle-Marcillac, for the French Adjuvant Study Group; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut Claudius Regaud, Toulouse, France; Centre Eugene Marquis, Rennes, France; Centre Rene Gauducheau, Nantes, France; Centre Hospitalier de Bretagne Sud, Lorient, France; Centre Antoine Lacassagne, Nice, France; Pharmacia SA, Guyancourt, France Abstract: We analyze retrospectively pattern of recurrence, disease-free (DFS) and overall survival (OS) in ILC pts compared to IDC, and determine prognostic factors and contribution of adjuvant treatments. Methods Among the 8 FASG trials, we selected 3295 pts (ILC = 337, IDC = 2958): 1510 received adjuvant chemotherapy (CT) (ILC = 140), 855 CT combined to tamoxifen (Tam) (ILC = 101), 615 Tam (ILC = 76), and 315 no systemic treatment (ILC = 20). In 2365 pts receiving CT, it was FEC regimens (epirubicin 50,75, or 100 mg/m2) in 85%, and other epirubicin (EPI)-based CT in the others. The median follow-up was 8 years (4-182 months). Univariate and multivariate analysis were performed on the whole population and in subgroups of pts receiving CT or no, adjusted to Tam. Results ILC pts were older than IDC (8.3% v 12.6% < 40 years, p=.02), underwent more mastectomy (56.4% v 40.1%, p<10-3) with equivalent tumor size (pT), presented a higher node (N) involvement (17.0% v 8.9% of N >/=10, p<10-3), and had more hormone receptors (HR) positive (87.0% v 72.9%, p<10-3). The 8-year DFS was not different both in univariate and multivariate analysis, but ILC had significantly more bone (p<10-3), abdominopelvis (p=.0008), medullary relapses (p=.0008), and less visceral (liver, lung) relapse (<10-3). There was no difference for local relapse and contralateral breast cancer. There was a trend for a worse OS in all ILC subgroups (p=.08). The multivariate analysis showed for both histology that prognostic factors of relapse were age < 40 years, N > 3, pT > 2 cm. In all groups of pts receiving CT, DFS was significantly better if EPI dose intensity > 30 mg/m2/wk for. If Tam had a positive contribution in HR+ IDC pts (p<10-3), it seemed to have no effect in ILC pts. Conclusion At diagnosis, ILC presented difference with IDC, but histology did not influence disease outcome even if the pattern of recurrence was different. Prognostic factors of relapse were classical. As regards systemic treatments, an increased EPI dose had a favorable contribution, but surprisingly in ILC pts, who presented more frequently HR+, Tam did not seem to be efficient. ASCO Abstract No: 54, 2003 Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.